Good morning, everyone. Damian Garde here, filling in for Ed Silverman once more in the waning days of the year, when out-of-office replies start to outnumber actionable emails and the workplace powers-that-be avert their eyes from just over your shoulder. Perhaps you’re using this time among the working few to chip away at long-delayed projects. Maybe you’re just passing the hours with the seemingly endless updates on a certain jailhouse romance. Either way, here as usual is a menu of tidbits to get your day rolling.

The European Union cleared Pfizer (PFE) and BioNTech’s (BNTX) Covid-19 vaccine and expects to start distributing it after Christmas, the Guardian tells us. The authorization is Europe’s first for a Covid-19 vaccine, and Pfizer said it’s prepared to immediately ship doses to the 27 member states from manufacturing sites in Germany and Belgium. Moderna’s (MRNA) vaccine is expected to receive the same clearance in early January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]